

4/6/2026
Neurocrine to Acquire Soleno Therapeutics, Expanding Rare Disease and Endocrinology Portfolio
The acquisition adds VYKAT™ XR (diazoxide choline), the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome (PWS), to Neurocrine’s growing portfolio of first-in-class therapies.
0
4 min read
Research Reports
Cocrystal Pharma (COCP) – CDI-988 Receives Fast Track Designation, Raising Its ProfileCP(Ocugen (OCGN) – Dosing Completed Early In The OCU410ST Phase 2/3 GARDian TrialO(DNutriband (NTRB) – First Marketing Partnership Expands Territory and Brings A Product ApprovalN(FSummit Midstream Corp (SMC) – Private Placement Financing Strengthens Balance Sheet and Enhances Financial FlexibilitySMC(
Welcome to the Channelchek Investor Community
We’ve updated the entire site to bring you faster navigation and increased content at every level. Channelchek is now North America’s leading platform for access to regulated and independent company sponsored equity research.